NCT03175029

Exploratory Study of TAC-302 in Detrusor Underactivity Patients With Overactive Bladder.

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 195 (actual)
• Sponsor: Taiho Pharmaceutical Co., Ltd. · Industry
• Sex: All
• Age: 20 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate the efficacy and safety of TAC-302 in detrusor underactivity patients with overactive bladder.

Detailed description

The main purpose of this study is to assess the efficacy of TAC-302 for 12 weeks in detrusor underactivity patients with overactive bladder by measuring the following parameters of pressure-flow study. * Male; bladder contractility index (BCI) * Female; projected isovolumetric pressure (PIP) 1

Conditions

• Detrusor Underactivity
• Overactive Bladder

Interventions

Type	Name	Description
DRUG	TAC-302	TAC-302 200 mg administered orally twice per day after meals, for 12 weeks.
DRUG	Placebo	Placebo administered orally twice per day after meals, for 12 weeks.

Timeline

• Start date: 2017-09-09
• Primary completion: 2019-11-01
• Completion: 2020-03-27
• First posted: 2017-06-05
• Last updated: 2025-01-20
• Results posted: 2025-01-20

Locations

1 site across 1 country: Japan